After the success of PSMA-targeted radiopharmaceuticals for prostate cancer imaging and therapy, the Auger emitter 125I was used to develop [125I]I-DCIBzL (20), which showed excellent antitumor efficacy in prostate cancer therapy compared with phosphate-buffered saline controls. The gene discussed is FOLH1; the disease is prostate carcinoma.